The class of "7420461P10Rik Inhibitors" comprises a diverse range of chemical compounds, each characterized by their unique biochemical properties and specific mechanisms of action. While these compounds are not directly linked to 7420461P10Rik due to limited scientific data, they are known to modulate various cellular signaling pathways that could indirectly influence the activity of proteins encoded by this gene.
Compounds like Alisertib, Dabrafenib, and Enzastaurin target crucial components of cell cycle regulation and signaling pathways such as Aurora A kinase, BRAF, and Protein kinase C, respectively. These pathways play significant roles in cell proliferation, differentiation, and survival. By modulating these pathways, these inhibitors could potentially influence the activity or expression of proteins encoded by genes like 7420461P10Rik.
Belinostat, a histone deacetylase inhibitor, affects gene expression and chromatin structure, potentially impacting proteins at a transcriptional level. Similarly, Cabozantinib and Lenvatinib, which inhibit various tyrosine kinases, including MET, VEGFR2, and FGFR, are significant in affecting pathways related to angiogenesis and cell growth. This alteration of pathways can have downstream effects on proteins involved in these processes, including those encoded by 7420461P10Rik.
Gilteritinib, Ibrutinib, and Midostaurin target specific kinases like FLT3, AXL, and Bruton's tyrosine kinase, playing a role in cell proliferation, apoptosis, and B-cell receptor signaling. These actions can indirectly affect proteins involved in these pathways. Nintedanib's inhibition of FGFR, PDGFR, and VEGFR affects fibrosis and angiogenesis pathways, potentially influencing proteins in these signaling cascades.
Palbociclib, a CDK4/6 inhibitor, impacts cell cycle regulation, potentially affecting proteins involved in cell proliferation and growth regulation. Regorafenib, as a multi-kinase inhibitor, exhibits broad-spectrum activity affecting processes like angiogenesis, tumor growth, and metastasis.
In summary, the "7420461P10Rik Inhibitors" class represents a comprehensive approach to understanding and modulating cellular signaling pathways. These compounds serve as valuable tools for research into the functional aspects of proteins and their role in various cellular processes. While direct inhibitors of 7420461P10Rik are not specified due to the lack of detailed information on the protein, this class of inhibitors presents a broad method for exploring the modulation of protein activity within complex cellular networks. Their diverse mechanisms of action, from targeting receptor tyrosine kinases to influencing gene expression, highlight the intricate balance of cellular processes and offer insights into the potential regulation of proteins encoded by genes like 7420461P10Rik.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
Aurora A kinase inhibitor, potentially affecting cell cycle regulation and mitosis. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $153.00 $561.00 | ||
Histone deacetylase inhibitor, potentially influencing gene expression and chromatin structure. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $92.00 $204.00 | 1 | |
Inhibits MET, VEGFR2, and RET tyrosine kinases, potentially affecting angiogenesis and cell growth. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $138.00 $255.00 $273.00 $403.00 $12240.00 | 6 | |
BRAF inhibitor, potentially affecting the MAPK/ERK signaling pathway. | ||||||
Enzastaurin | 170364-57-5 | sc-364488 sc-364488A sc-364488B | 10 mg 50 mg 200 mg | $254.00 $600.00 $1687.00 | 3 | |
Protein kinase C inhibitor, potentially influencing cell proliferation and survival pathways. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Bruton's tyrosine kinase inhibitor, potentially affecting B-cell receptor signaling. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $178.00 $648.00 $1657.00 | 3 | |
Inhibits VEGFR, FGFR, PDGFR, RET, and KIT, potentially affecting angiogenesis and cell proliferation. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $180.00 $315.00 | 2 | |
Inhibits FGFR, PDGFR, and VEGFR, potentially affecting fibrosis and angiogenesis pathways. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
CDK4/6 inhibitor, potentially influencing cell cycle regulation and proliferation. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Multi-kinase inhibitor, potentially affecting angiogenesis, tumor growth, and metastasis. | ||||||